Low blood sugar on GLP-1 medications

Trial rates by situation

The labels measure low blood sugar in slightly different ways, so each row names its threshold. Ranges cover dose groups, and rates from different trials cannot be directly compared ^[1][2][3][5].

What the European product information adds

The European summaries of product characteristics sort side effects into frequency bands: very common means more than 1 in 10 people, common up to 1 in 10, uncommon up to 1 in 100. Both the Ozempic® and Mounjaro® leaflets place low blood sugar in the very common band when the medicine is combined with a sulfonylurea or insulin ^[7][8]. Ozempic® moves to common when it is combined with other diabetes tablets, and the Wegovy® leaflet lists it as common in people with type 2 diabetes ^[7][9].

Two details do not appear in the US tables. In the SUSTAIN 9 trial, low blood sugar meeting the American Diabetes Association definition occurred in 11.3% of people when semaglutide 1 mg was added to an SGLT2 inhibitor, against 2.0% on placebo, and severe episodes in 0.7% against none ^[7]. The Mounjaro® leaflet also lists low blood sugar as common when tirzepatide is taken with both metformin and an SGLT2 inhibitor ^[8].

Severe episodes stayed rare overall. Across the tirzepatide phase 3 programme, 10 people (0.2%) reported 12 severe episodes, and five of those ten were also on insulin glargine or a sulfonylurea ^[8]. The European label for Ozempic® also notes that people combining it with a sulfonylurea or insulin should take care to avoid low blood sugar while driving or using machines ^[7].

What a head-to-head trial reported

SURPASS-2, a randomised trial published in 2021, compared three tirzepatide doses with semaglutide 1 mg in adults with type 2 diabetes who were already taking metformin. Readings below 54 mg/dL were reported in 0.6%, 0.2% and 1.7% of the three tirzepatide groups and in 0.4% of the semaglutide group ^[10].

There was no placebo arm, and the people enrolled were not using insulin or a sulfonylurea, so these figures describe the lower-risk setting. They are not a ranking of the two medicines.

Why it happens: three layers

• What the labels state: the Ozempic® label explains that the medicine stimulates insulin release when blood glucose is raised, which is why low readings were uncommon when GLP-1 medicines were used alone ^[1]. The Wegovy® and Zepbound® labels still say plainly that the medicine lowers blood glucose and can cause hypoglycemia ^[2][5].
• Where the risk mostly comes from: MedlinePlus explains that low blood sugar in diabetes is usually tied to insulin or certain other diabetes medicines, while many others do not cause it ^[11]. NIDDK names sulfonylureas among the tablets that can, because they raise insulin over several hours ^[12].
• Everyday situations: NIDDK lists eating too few carbohydrates, skipping or delaying meals, fasting before a procedure while still taking glucose-lowering medicines, more physical activity than usual, alcohol without food, and being unwell ^[12]. Eating less is an expected effect of GLP-1 medicines, but the labels do not measure how much it adds to the risk, so treat this as general guidance rather than a finding about these drugs.

Who carries more risk

Sulfonylureas and insulin are the main factor named in every label. With a sulfonylurea, severe low blood sugar, meaning an episode that needed another person’s help, occurred in 0.8% to 1.2% of people on Ozempic®; readings below 54 mg/dL occurred in 9.9% to 13.8% on Mounjaro® over up to 104 weeks ^[1][3]. In the Zepbound® diabetes trial, 10.3% of people also taking a sulfonylurea had low readings, against 2.1% of those who were not ^[5].

The Wegovy® label adds that people with a history of bariatric surgery, itself a risk factor, had more serious low blood sugar on Wegovy® (2 of 87) than on placebo (none of 97) in its cardiovascular trial ^[2]. In children aged 10 and older on Mounjaro® with basal insulin, in groups of about ten each, readings below 54 mg/dL occurred in 27% to 30%, against 10% on placebo ^[3].

In the weight-reduction trials in adults without type 2 diabetes, low blood sugar was not systematically captured. The Zepbound® label reports readings below 54 mg/dL in 0.3% of people on the medicine and none on placebo. The Wegovy® label notes that episodes have been reported with GLP-1 medicines in adults without diabetes, and that its cardiovascular trial recorded 3 serious episodes on Wegovy® against 1 on placebo ^[2][5].

Signs the Medication Guides list

MedlinePlus treats a reading below 70 mg/dL as low and notes that more serious symptoms, such as unclear thinking or a seizure, tend to appear when it falls much further, below 54 mg/dL ^[11]. It also describes hypoglycemia unawareness: some people notice no warning signs at all, which is one reason a reading matters more than a feeling.

• Dizziness or light-headedness, blurred vision, slurred speech ^[4][6].
• Sweating, shakiness, feeling jittery, a fast heartbeat.
• Hunger, weakness, headache.
• Confusion or drowsiness, anxiety, irritability or mood changes.

When it may be something else

Several of these signs overlap with other reactions the same labels describe. Dizziness can come from low blood pressure or from fluid loss on days of vomiting or diarrhea, and shakiness or a racing heart can have everyday causes. MedlinePlus is clear that low blood sugar is confirmed by a reading, not by symptoms alone ^[11].

In people without diabetes, MedlinePlus lists other causes of low blood sugar, including alcohol, some types of weight-loss surgery several years later, hormone problems, serious illness and certain non-diabetes medicines ^[11]. Working out which one applies is your clinician’s job.

What the guides say helps

• Before you start: the Ozempic®, Mounjaro® and Zepbound® Medication Guides ask you to go over low blood sugar with your provider, including how you would handle an episode, and to mention any insulin or sulfonylurea you use ^[1][4][6]. The Wegovy® guide asks people with type 2 diabetes to check blood sugar before starting and during treatment ^[2].
• Have a plan: MedlinePlus says your provider should teach you how to treat a low yourself, for example with juice, food or glucose tablets ^[11]. NIDDK describes the standard approach of a measured amount of fast-acting carbohydrate, a short wait, a recheck and a repeat if still low; the amounts and your target belong in the plan your care team gives you ^[12].
• Carry something and eat with alcohol: NIDDK suggests keeping a fast-acting carbohydrate with you and eating when you drink ^[12].
• Around exercise: activity can lower blood glucose during and for hours afterwards, so NIDDK suggests checking before, during and after if your medicines can cause lows ^[12].
• For a severe low: NIDDK describes glucagon, an injection or nasal spray your doctor can prescribe, teaching family and coworkers how to use it, and wearing a medical ID ^[12].
• For prescribers: each label says the dose of insulin or a sulfonylurea may be reduced when the GLP-1 medicine is started ^[1][3][5]. That decision is theirs, which is why it matters that they know everything you take.

What to write down

If you have an episode, note the time, what you felt, and the reading if you measured one. Add when and how much you last ate, any exercise or alcohol, when you took your GLP-1 dose and any other diabetes medicines, and how long it took to pass. Patterns such as episodes after skipped meals, or in the days after a dose increase of another medicine, are exactly what your prescriber needs to see.

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.